Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Olaparib in HRD-positive TNBC
NCT07005583Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in triple-negative breast cancer (TNBC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 2 years. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07005583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005583.